RT Journal Article
T1 The effectiveness of daclatasvir based therapy in European patients with chronic hepatitis C and advanced liver disease.
A1 Young, Jim
A1 Weis, Nina
A1 Hofer, Harald
A1 Irving, William
A1 Weiland, Ola
A1 Giostra, Emiliano
A1 Pascasio, Juan Manuel
A1 Castells, Lluis
A1 Prieto, Martin
A1 Postema, Roelien
A1 Lefevre, Cinira
A1 Evans, David
A1 Bucher, Heiner C
A1 Calleja, Jose Luis
K1 Daclatasvir
K1 Direct-acting antivirals
K1 Effectiveness
K1 Hepatitis C
K1 Sofosbuvir
AB There is limited evidence for the effectiveness of daclatasvir in patients whose hepatitis C threatens their life expectancy. The Named Patient Program in Europe included patients with advanced chronic hepatitis C, a life expectancy of less than 12 months and no other treatment options. A retrospective multi-country cohort of patients with chronic hepatitis C who received daclatasvir as part of the Named Patient Program in Austria, Denmark, Spain, Sweden, Switzerland and the United Kingdom. Treatment response was defined as a sustained virologic response (unquantifiable hepatitis C RNA) at 12 weeks post treatment. We summarised the characteristics of the patients in this cohort and estimated the rate of sustained virologic response for patients receiving daclatasvir and sofosbuvir with or without ribavirin using hierarchical Bayesian modelling. The 249 patients included had a median age of 56 years; most were male (78%), hepatitis C genotype 1 (75%), treatment experienced (65%) and with decompensated cirrhosis (59%). Many had had a liver transplant before receiving daclatasvir (40%). Of the 249 patients, 242 patients received daclatasvir and sofosbuvir and either reached 12 weeks post treatment or died during (n = 9) or after treatment (n = 4) or were lost to follow up during treatment (n = 1). The estimated rate of sustained virologic response at 12 weeks post treatment was 87% (95% credible interval 75 to 94%) for previously treated genotype 1 patients with decompensated cirrhosis. Daclatasvir with sofosbuvir is an effective treatment in clinical practice for hepatitis C genotype 1 patients with decompensated cirrhosis.
YR 2017
FD 2017-01-07
LK http://hdl.handle.net/10668/10747
UL http://hdl.handle.net/10668/10747
LA en
DS RISalud
RD Apr 4, 2025